Medtronic to spin off its diabetes business into a standalone, publicly traded company within 18 months, aiming to streamline its portfolio and focus on high-margin growth sectors.
VF Corp's Q4 results show operational improvements, but weak guidance disappoints investors.
Medtronic to spin off its diabetes business into a standalone, publicly traded company within 18 months, aiming to streamline its portfolio and focus on high-margin growth sectors.
VF Corp's Q4 results show operational improvements, but weak guidance disappoints investors.
We use cookies to personalize content and ads, to provide social media features, and to analyze our traffic. We also share information about your use of our site with our social media, advertising, and analytics partners.
By continuing to use our site, you consent to our cookies. You can manage your preferences or withdraw your consent at any time by clicking on the buttons below.